Autologous Chondrocyte Transplantation-Series of 3 Cases

Gobbi, Riccardo Gomes; Demange, Marco Kawamura; Silva, Ronald Bispo Barreto da; Pécora, José Ricardo; Rezende, Márcia Uchôa de; Filho, Tarcísio Eloy Pessoa Barros; Lombello, Christiane Bertachini

doi:10.1016/s2255-4971(15)30396-7

Cited by 4 publications

(5 citation statements)

References 23 publications

(35 reference statements)

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Although they did not describe the complications that occurred, they reported little improvement and maintenance of pain in all three cases, suggesting treatment failure. (24) In 2020, Giglio et al (25) presented the results of 11 patients treated with chondrocytes in the membrane, with a different cell therapy product production protocol from this study. The authors reported the occurrence of complications in four cases: two evolved with adhesions and joint stiffness, requiring reoperations to recover motion; one had an infection of the surgical wound at the site of bone graft removal, and one presented with implant hypertrophy.…”

Section: ❚ Discussionmentioning

confidence: 91%

Matrix-assisted autologous chondrocyte transplantation for treatment of focal chondral lesions in the knee: the Hospital Israelita Albert Einstein experience

Zorzi¹,

Antonioli²,

Kaleka³

et al. 2022

Einstein (São Paulo)

View full text Add to dashboard Cite

Objective: Phase 1 clinical trial to determine feasibility, safety, and efficacy of a new advanced cell therapy product for treatment of knee articular cartilage injuries. Methods: Three participants with knee focal chondral lesions were included, with no signs of osteoarthritis. Chondrocytes were obtained through knee arthroscopy, cultured in collagen membrane for 3 weeks at the laboratory, subjected to tests to release the cell therapy product, and implanted. All patients underwent a specific 3-month rehabilitation protocol, followed by assessments using functional and imaging scales. The main outcome was the incidence of severe adverse events. Results: Three participants were included and completed the 2-year follow-up. There was one severe adverse event, venous thrombosis of distal leg veins, which was no associated with therapy, was treated and left no sequelae. The clinical and radiological scales showed improvement in the three cases. Conclusion: The preliminary results, obtained with the described methodology, allow concluding that this product of advanced cell therapy is safe and feasible. ReBEC platform registration number: RBR-6fgy76

show abstract

Section: ❚ Discussionmentioning

confidence: 91%

Matrix-assisted autologous chondrocyte transplantation for treatment of focal chondral lesions in the knee: the Hospital Israelita Albert Einstein experience

Zorzi¹,

Antonioli²,

Kaleka³

et al. 2022

Einstein (São Paulo)

View full text Add to dashboard Cite

show abstract

“…Currently, extensive commercial cell culture therapies, such as autologous chondrocyte transplantation, are not available in the country. 12 The availability of allogeneic transplantation 13 , 14 and collagen membranes is also limited. The instruments for autologous osteochondral transplantation are not available in most centers of the Brazilian Unified Health System.…”

Section: Discussionmentioning

confidence: 99%

Femoral condyle osteochondral fracture treated with bone suture after acute patellar dislocation: a case report

Cavalheiro

Gobbi

Hinckel

et al. 2018

Revista Brasileira de Ortopedia (English Edition)

Self Cite

View full text Add to dashboard Cite

Osteochondral fracture after acute patellar dislocation in teenagers is relatively common (up to 60% of cases of patellar dislocation), but poorly diagnosed. There are several treatments proposed for this type of injury, but none well defined in the literature.A male patient, 13 years old, with a diagnosis of osteochondral fracture of the lateral femoral condyle after acute dislocation of the right patella. He underwent surgical treatment of the chondral injury, which consisted of suturing of the chondral fragment to the cartilage defect and, in a second approach, reconstruction of the medial patellotibial ligament and medial patellofemoral ligament with autologous flexor graft. Currently, the patient has been followed up for 16 months postoperatively for the suture of the chondral fragment and for 8 months for the ligament reconstruction. He has been evaluated through functional scores and T2 weighted magnetic resonance imaging. Acute fixation through direct bone suturing of a purely chondral fragment can be considered in special situations.

show abstract

“…8 In Brazil, experiences with ACI and other cellular therapies for cartilage regeneration are incipient. After the initial application of first-generation technique, 9,10 there was a period in which other techniques were not available. The aim of this study was to establish an ACI clinical routine for knee cartilage injuries and report the experience with a six-month minimum follow-up, focusing on feasibility, patient safety and evaluation of adverse events and functional outcome.…”

Section: Introductionmentioning

confidence: 99%

Autologous Chondrocyte Implantation in Brazil

Giglio

Lizier²,

Levy

et al. 2020

Acta ortop. bras.

Self Cite

View full text Add to dashboard Cite

Objective: To describe the first series of cases of autologous chondrocyte implantation (ACI) in collagen membrane performed in Brazil. Methods: ACI was performed in 12 knees of 11 patients, aged 32.1 ± 10.9 years, with 5.3 ± 2.6 cm2 full-thickness knee cartilage lesions, with a six-month minimum follow-up. Two surgical procedures were performed: arthroscopic cartilage biopsy for isolation and expansion of chondrocytes, which were seeded onto collagen membrane and implanted in the lesion site; the characterization of cultured cells and implant was performed using immunofluorescence for type II collagen (COL2) for cell viability and electron microscopy of the implant. Clinical safety, KOOS and IKDC scores and magnetic resonance imaging were evaluated. We used repeated-measures ANOVA and post-hoc comparisons at α = 5%. Results: COL2 was identified in the cellular cytoplasm, cell viability was higher than 95% and adequate distribution and cell adhesion were found in the membrane. The median follow-up was 10.9 months (7 to 19). We had two cases of arthrofibrosis, one of graft hypertrophy and one of superficial infection as complications, but none compromising clinical improvement. KOOS and IKDC ranged from 71.2 ± 11.44 and 50.72 ± 14.10, in preoperative period, to 85.0 ± 4.4 and 70.5 ± 8.0, at 6 months (p = 0.007 and 0.005). MRI showed regenerated tissue compatible with hyaline cartilage. Conclusion: ACI in collagen membrane was feasible and safe in a short-term follow-up, presenting regenerated formation visualized by magnetic resonance imaging and improved clinical function. Level of evidence IV, Case series.

show abstract

Autologous Chondrocyte Transplantation-Series of 3 Cases

Cited by 4 publications

References 23 publications

Matrix-assisted autologous chondrocyte transplantation for treatment of focal chondral lesions in the knee: the Hospital Israelita Albert Einstein experience

Matrix-assisted autologous chondrocyte transplantation for treatment of focal chondral lesions in the knee: the Hospital Israelita Albert Einstein experience

Femoral condyle osteochondral fracture treated with bone suture after acute patellar dislocation: a case report

Autologous Chondrocyte Implantation in Brazil

Contact Info

Product

Resources

About